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The microenvironment of a tumor is known to influence tumor progression and spread to distant 
sites (metastasis). Padua et al. (2008) now show that transient exposure of breast cancer cells 
to the signaling molecule transforming growth factor β (TGFβ) promotes their extravasation 
from blood vessels and entry into the lung by upregulation of the adipokine angiopoietin-like 4 
(ANGPTL4). Their work shows that the later stages of metastasis can be influenced by transient 
signals produced in the primary tumor microenvironment.Metastasis is a leading cause of mortal-
ity for cancer patients, yet the molecular 
mechanisms underlying metastasis are still 
poorly understood. It was established more 
than 100 years ago that particular tumor 
types have a propensity to metastasize to 
certain organs (Paget, 1889); for example, 
breast tumor cells tend to metastasize to 
lung, bones, brain, and liver. We now know 
that this nonrandom distribution of metas-
tases is independent of vascular anatomy, 
rate of blood flow, and the number of 
tumor cells delivered to each organ (Fidler, 
2003). Instead, metastases may be due to 
expression of particular genes within the 
tumor cells that drive their invasion of a 
particular organ (Kang et al., 2003; Minn 
et al., 2005). Cancer cells must succeed in 
multiple feats to successfully seed a new 
tissue site. First, they escape from the pri-
mary tumor and invade local tissue; then, 
they enter the bloodstream or lymphatic 
system where they must survive; finally, 
they move from the blood stream into tis-
sues (extravasation) that are far from the 
primary tumor site and adapt to or modify 
the metastatic niche to establish a new 
tumor. In this issue, Padua et al. (2008) dis-
cover that the growth factor TGFβ primes 
human tumor cells for lung metastasis by 
driving expression of the adipokine angio-
poietin-like 4 (ANGPTL4), which enables 
the tumor cells to extravasate into the lung 
by disrupting capillary vascular endothelial 
cell junctions.
Although most studies exploring the 
molecular mechanisms of metastasis 
have focused on features intrinsic to tumor 
cells, the tumor microenvironment also plays an important role (McSherry et al., 
2007). Primary carcinomas, as well as 
metastases, are comprised of both tumor 
cells and cells of the stroma including 
fibroblasts, endothelial cells, and inflam-
matory cells (Figure 1). There is strong 
evidence that interactions between the 
tumor cells and the stroma influence can-
cer growth and metastasis (Karnoub et al., 
2007; Lin et al., 2001; Olumi et al., 1999). 
One accepted role for stromal cells dur-
ing metastasis is to enhance the ability of 
tumor cells to leave the primary tumor and 
to invade local tissue. However, extrava-
sation and tumor establishment at sites 
distant from the primary tumor are limiting 
steps of metastasis, and the ways in which 
the primary tumor microenvironment may 
promote these later stages of metastasis 
is still unclear.
One factor that is produced abundantly 
by stromal cells in the tumor microenvi-
ronment is transforming growth factor β 
(TGFβ). TGFβ is a multifunctional growth 
factor with a complicated dual role in tum-
origenesis (Leivonen and Kahari, 2007). 
Figure 1. TGFβ Influences Tumor Growth and Metastasis
The cytokine TGFβ is produced by stromal cells of the tumor microenvironment in response to hypoxia 
or inflammation, or by carcinoma-associated fibroblasts (CAFs). Cancer cells in advanced tumors are un-
responsive to the growth inhibitory effects of TGFβ and instead respond to this factor by increasing their 
growth, survival, motility, and invasion, and by undergoing an epithelial-to-mesenchymal transition (EMT). 
In addition to these effects, TGFβ stimulates expression of the adipokine angiopoietin-like 4 (ANGPTL4) 
by activating SMAD transcription factors. Secretion of ANGPTL4 enables tumor cells to extravasate into 
lung tissue and to seed micrometastases.Cell 133, April 4, 2008 ©2008 Elsevier Inc. 27
During the early stages of tumor forma-
tion, TGFβ acts as a tumor suppressor, 
inhibiting proliferation and inducing apop-
tosis of tumor cells. During later stages 
of tumorigenesis, however, many tumor 
cells become unresponsive to the growth 
inhibitory functions of TGFβ, and instead 
respond to this growth factor by becom-
ing more motile, more invasive, and more 
resistant to apoptosis. Furthermore, TGFβ 
is induced in response to hypoxia and 
inflammation and can have a protective 
effect on tumor cells. TGFβ has also been 
observed to drive an epithelial-to-mesen-
chymal transition in cancer cells, which 
increases their metastatic capability.
In their new study, Padua et al. (2008) 
examine the role of TGFβ produced by 
stromal cells in the metastasis of breast 
tumor cells to the lung. The authors used a 
gene-expression microarray approach to 
define a group of target genes expressed 
by human breast tumor cells in response to 
TGFβ exposure. They found that the TGFβ-
response signature (TBRS) correlated with 
metastasis to lung tissue in patients with 
estrogen receptor (ER)-negative breast 
cancer. No link was identified between the 
TBRS and metastasis to bone, or metasta-
sis of ER-positive breast tumor cells.
Comparison of gene-expression profiles 
between the TBRS and a lung metastasis 
signature (LMS) (Minn et al., 2005) revealed 
that ER-negative breast tumors scoring 
positive for both the TBRS and the LMS 
were uniquely associated with a high risk 
of lung metastasis. To test the requirement 
for TGFβ in metastasis of ER-negative 
breast cancer cells, the authors turned to 
an ER-negative human breast cancer cell 
line, LM2, which had been selected exper-
imentally for the capability to metastasize 
to lung (Minn et al., 2005). Blocking TGFβ 
signaling led to reduced metastasis to the 
lungs of recipient mice, but did not affect 
tumor growth or intravasation. These data 
suggest that TGFβ is critical for ER-nega-
tive breast tumor cells to complete one or 
more of the later stages of metastasis, that 
is, survival in the bloodstream, extravasa-
tion, or colonization of the lungs.
Experimental metastasis assays, which 
involve direct inoculation of tumor cells 
into the bloodstream of mice, measure the 
ability of cells to extravasate, and colo-
nize a distant organ. The authors asked 
whether prior exposure of ER-negative 
human breast tumor cells to TGFβ in vitro 28 Cell 133, April 4, 2008 ©2008 Elsevier Inccould influence the ability of the tumor cells 
to complete the final steps of metastasis 
to lung. Treatment of the tumor cells with 
TGFβ for a short time prior to intravenous 
injection into mice significantly increased 
the number of cells detected in the lung in 
the first 24 hr after inoculation. Because 
this effect was not sustained through out-
growth of metastatic colonies, the data 
suggested that TGFβ selectively primes 
tumor cells for extravasation to lung.
Analysis of two genes whose expres-
sion overlapped between the TBRS and 
the LMS profiles led the authors to identify 
ANGPTL4 as a possible mediator of TGFβ-
mediated lung colonization. TGFβ signal-
ing induced expression of ANGPTL4 in a 
number of cultured tumor cell lines, and 
also in primary malignant pleural cell effu-
sion samples from breast cancer patients. 
Remarkably, blocking ANGPTL4 expres-
sion using short hairpin RNAs inhibited 
lung metastases from LM2 breast can-
cer cell xenografts in mouse mammary 
glands. The investigators showed that this 
effect was due to decreased extravasation 
of the tumor cells into the lung. Secretion 
of ANGPTL4 by the breast cancer cell line 
led to disruption of junctions between vas-
cular endothelial cells, causing increased 
permeability of lung capillaries. Together, 
these results suggest that exposure to 
TGFβ produced by the stroma imbues ER-
negative breast cancer cells with the abil-
ity to form metastatic lesions when they 
reach the lung. Interestingly, exposure of 
breast tumor cells to TGFβ had no effect 
on their ability to colonize bone follow-
ing injection into the arterial circulation of 
recipient mice, presumably because of the 
absence of vascular endothelial junctions 
in the bone marrow vasculature.
Just as multiple steps are required for 
tumor formation, it is likely that tumor pro-
gression and metastasis are a result of 
multiple gene products acting in concert 
with one another. The Padua et al. study 
demonstrates how the elegant strategy of 
gene-expression profiling combined with 
clinical outcome information (Bild et al., 
2006) can shed light on the role of stromal 
components of the tumor microenviron-
ment in metastasis. By focusing on criti-
cal downstream elements of TGFβ signal-
ing during metastasis, the authors have 
identified a functional role for ANGPTL4 in 
the extravasation step that enables breast 
tumor cells to colonize lung tissue..The pleiotropic roles of TGFβ serve 
as an excellent example of how a func-
tional gain in a given signaling pathway 
in the primary tumor can provide a selec-
tive advantage both in primary tumor 
growth and in the development of distant 
metastases. Even if the upregulation of 
ANGPTL4 is an incidental “side effect” of 
exposure to TGFβ in the primary tumor, 
it clearly provides an advantage to tumor 
cells at later stages of tumorigenesis and 
metastasis. Given that the effects of TGFβ 
and ANGPTL4 on metastasis were spe-
cific for ER-negative breast tumor cells, it 
is likely that there are additional cooper-
ating factors that contribute to this pro-
cess. Interestingly, mesenchymal stem 
cells can also stimulate extravasation of 
the same ER-negative breast cancer cell 
line by upregulating the chemokine CCL5 
(Karnoub et al., 2007). Together, these 
studies provide new compelling evidence 
that metastasis is regulated by contextual 
signals that tumor cells receive from their 
microenvironment.
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